Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.19
CUR's Cash to Debt is ranked higher than
62% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. CUR: 2.19 )
CUR' s 10-Year Cash to Debt Range
Min: 0.22   Max: No Debt
Current: 2.19

Equity to Asset 0.43
CUR's Equity to Asset is ranked higher than
57% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CUR: 0.43 )
CUR' s 10-Year Equity to Asset Range
Min: -8.17   Max: 0.87
Current: 0.43

-8.17
0.87
F-Score: 2
Z-Score: 6.54
M-Score: 5.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -11385.45
CUR's Operating margin (%) is ranked lower than
52% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. CUR: -11385.45 )
CUR' s 10-Year Operating margin (%) Range
Min: -11385.45   Max: -507.12
Current: -11385.45

-11385.45
-507.12
Net-margin (%) -18029.09
CUR's Net-margin (%) is ranked lower than
53% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. CUR: -18029.09 )
CUR' s 10-Year Net-margin (%) Range
Min: -18029.09   Max: -534.63
Current: -18029.09

-18029.09
-534.63
ROE (%) -235.56
CUR's ROE (%) is ranked lower than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. CUR: -235.56 )
CUR' s 10-Year ROE (%) Range
Min: -754.16   Max: -90.67
Current: -235.56

-754.16
-90.67
ROA (%) -102.15
CUR's ROA (%) is ranked higher than
51% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. CUR: -102.15 )
CUR' s 10-Year ROA (%) Range
Min: -1813.79   Max: -78.89
Current: -102.15

-1813.79
-78.89
ROC (Joel Greenblatt) (%) -5421.65
CUR's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. CUR: -5421.65 )
CUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9581.82   Max: -1662.3
Current: -5421.65

-9581.82
-1662.3
Revenue Growth (%) -100.00
CUR's Revenue Growth (%) is ranked lower than
51% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. CUR: -100.00 )
CUR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 26
Current: -100

0
26
EBITDA Growth (%) -10.60
CUR's EBITDA Growth (%) is ranked higher than
73% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. CUR: -10.60 )
CUR' s 10-Year EBITDA Growth (%) Range
Min: -17.2   Max: 35.7
Current: -10.6

-17.2
35.7
EPS Growth (%) -13.70
CUR's EPS Growth (%) is ranked higher than
73% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. CUR: -13.70 )
CUR' s 10-Year EPS Growth (%) Range
Min: -40.6   Max: 32.2
Current: -13.7

-40.6
32.2
» CUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CUR



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 33.90
CUR's P/B is ranked lower than
75% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CUR: 33.90 )
CUR' s 10-Year P/B Range
Min: 3.91   Max: 141.33
Current: 33.9

3.91
141.33
P/S 2460.30
CUR's P/S is ranked lower than
95% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. CUR: 2460.30 )
CUR' s 10-Year P/S Range
Min: 0   Max: 2662
Current: 2460.3

0
2662
EV-to-EBIT 20.40
CUR's EV-to-EBIT is ranked higher than
54% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. CUR: 20.40 )
CUR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 20.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 47.30
CUR's Price/Net Cash is ranked lower than
86% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. CUR: 47.30 )
CUR' s 10-Year Price/Net Cash Range
Min: 13.63   Max: 60
Current: 47.3

13.63
60
Price/Net Current Asset Value 47.30
CUR's Price/Net Current Asset Value is ranked lower than
85% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. CUR: 47.30 )
CUR' s 10-Year Price/Net Current Asset Value Range
Min: 13.63   Max: 60
Current: 47.3

13.63
60
Price/Tangible Book 42.00
CUR's Price/Tangible Book is ranked lower than
89% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CUR: 42.00 )
CUR' s 10-Year Price/Tangible Book Range
Min: 12.11   Max: 60
Current: 42

12.11
60
Price/Median PS Value 3.60
CUR's Price/Median PS Value is ranked lower than
68% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CUR: 3.60 )
CUR' s 10-Year Price/Median PS Value Range
Min: 0.91   Max: 2.68
Current: 3.6

0.91
2.68
Forward Rate of Return (Yacktman) -17.45
CUR's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. CUR: -17.45 )
CUR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -156.4   Max: -21.2
Current: -17.45

-156.4
-21.2

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:7NS.Germany
Neuralstem, Inc. was incorporated in 1997 in the state of Maryland. In 2001 it re-incorporated in the state of Delaware. It is development stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form the proprietary base of its research and development efforts in the area of neural stem cell research, and related technologies. Its technology base, in combination with its know-how, and collaborative projects with major research institutions, provide a competitive advantage and would facilitate the successful development and commercialization of products for use in treatment of an array of neurodegenerative conditions and in regenerative repair of acute disease. The Company is focused on leveraging its key assets, including its intellectual property, its scientific team, its facilities and its capital, to accelerate the advancement of its stem cell technologies. In addition, it is pursuing strategic collaborations with members of academia. The Company manufactures its cells both in-house and on an outsource basis. It uses these cells in its research and collaborative programs. It outsources all the manufacturing and storage of its stem cells to be used in pre-clinical works, and which are accordingly subject to higher FDA requirements, to Charles River Laboratories, Inc., of Wilmington, Massachusetts. The Company's competitors include major multinational pharmaceutical companies, specialty biotechnology companies and chemical and medical products companies operating in the fields of regenerative medicine, cell therapy, tissue engineering and tissue regeneration. Many of these companies are well-established and possess technical, research and development, financial and sales and marketing resources greater than the Company. The Company is subject to various U.S. federal, state, local and international laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its business.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide